The North America Ophthalmology Drugs & Devices Market was valued at USD 15,400 million in 2025 and is projected to reach USD 33,510 million by 2035, expanding at a CAGR of 7.5% from 2024 to 2035. The market is driven by an increasing aging population, a surge in chronic eye disorders, advancements in minimally invasive surgical devices, and robust innovation from leading pharmaceutical and medical device companies like Alcon, Johnson & Johnson Vision, and Novartis.
The economic impact of tariffs on "North America Ophthalmology Drugs & Devices Market".
Market Growth Drivers
Rising Prevalence of Age-Related Eye Diseases: The increasing incidence of age-related disorders such as glaucoma, cataract, and macular degeneration significantly boosts the demand for ophthalmic drugs and devices in North America. With a large proportion of the population over 60 years, there is a prevalent need for therapeutic and surgical interventions. Companies like Alcon and Novartis have augmented research into advanced intraocular lenses and anti-VEGF drugs to address these challenges, further uplifting the market.
Technological Innovation in Surgical Devices: The proliferation of advanced technologies in ophthalmic surgeries, such as femtosecond lasers and minimally invasive glaucoma surgeries (MIGS), is reshaping patient outcomes and physician preferences. Johnson & Johnson Vision and Zeiss have launched state-of-the-art devices that enhance precision, reduce recovery times, and improve patient safety, fueling the market's growth trajectory.
Market Trends
Integration of Artificial Intelligence and Digital Platforms: The adoption of AI-powered diagnostic and monitoring tools for ophthalmology is rapidly growing. Companies such as Topcon and Carl Zeiss are deploying AI-based retinal screening platforms that enable early detection of diabetic retinopathy and macular degeneration. The convergence of cloud data management with AI is streamlining diagnostic accuracy and facilitating remote patient monitoring, drastically transforming the traditional treatment paradigm.
Shift Towards Sustained Drug Delivery Systems: There is a growing trend towards sustained drug delivery devices, such as ocular implants and biodegradable inserts that provide longer-lasting therapeutic effects with fewer interventions. Genentech, for instance, has developed the Port Delivery System with ranibizumab, approved by the FDA, that demonstrates durable efficacy for macular degeneration. This trend is reducing patient burden and driving greater adherence to ophthalmic treatments.
Market Opportunities
Expansion of Teleophthalmology: The post-pandemic shift toward telemedicine is opening substantial opportunities for remote diagnosis, follow-up care, and management of chronic eye disorders. Platforms provided by American Well and VSP Vision are enabling virtual consultations and digital eye exams, improving access in underserved regions.
R&D for Pediatric Ophthalmic Treatments: There are untapped opportunities in developing pediatric-specific ophthalmology drugs and devices. Companies like Santen Pharmaceuticals are investing in tailored drug formulations and smart diagnostic devices for conditions such as pediatric myopia and amblyopia, paving the way for market expansion.
North America Ophthalmology Drugs & Devices Market Revenue (USD Million), 2020-2035
The market revenue chart demonstrates robust growth for North America’s ophthalmology drugs and devices sector from 2020 to 2035. Starting from USD 9,400 million in 2020, there is a steady upward trend, reaching USD 15,400 million in 2025 and projected to hit USD 33,510 million by 2035. The chart highlights the positive impact of technological advancements, chronic disease prevalence, and an aging demographic. The most significant acceleration is observed post-2025, concurrent with the launch of AI-driven diagnostics and sustained-release drug delivery platforms. This ongoing momentum suggests major investments and innovations on the horizon.
North America Ophthalmology Drugs & Devices Market Share by Region (%), 2025
The 2025 regional market share pie chart reveals that the United States is the dominant contributor, holding 82% of the North America ophthalmology drugs & devices market, mainly due to its large patient base, advanced healthcare infrastructure, and rich environment for innovation. Canada accounts for 13%, benefitting from increasing government healthcare investment and a rising elderly population. Mexico holds 4% of the market, with growth spurred by improving access and public health initiatives. ‘Others’ (including the Caribbean and Central American countries) share 1% collectively. This distribution highlights the strong market concentration in the U.S. and emerging potential across the rest of North America.
Recent Developments in North America Ophthalmology Drugs & Devices Market
In March 2024, Alcon announced the FDA approval and U.S. launch of its Clareon family of intraocular lenses, designed to provide superior clarity and stability post-cataract surgery. The innovation leverages hydrophobic acrylic material that resists glistening and enhances vision quality for cataract patients.
In April 2024, Johnson & Johnson Vision introduced the TECNIS Synergy Toric II IOL, expanding its multifocal intraocular lens portfolio across North America. The lens offers extended depth of focus and improved astigmatism correction, addressing a broad demographic of cataract patients seeking both near and distance vision restoration.
In May 2024, Genentech (a member of the Roche Group) received Health Canada approval for Vabysmo™ (faricimab) for treating diabetic macular edema and age-related macular degeneration. This therapy is the first to target both Ang-2 and VEGF-A, representing a significant advancement for patients with refractory retinal conditions.
Press Releases